Personalized Medicine Coalition

What Personalized Medicine Coalition does

The Personalized Medicine Coalition (PMC) is a nonprofit membership-based advocacy and education organization founded in 2004 and headquartered in Washington, D.C. The organization promotes the understanding and adoption of personalized medicine concepts, services, and products through three coordinated activities: education of decision-makers and the public, advocacy for biomedical research investment and modernized regulatory and reimbursement policies, and evidence development to demonstrate the clinical and economic value of personalized medicine. PMC does not develop or sell technology products; its core output is convening, policy engagement, and published research. The organization works in close coordination with the bipartisan Congressional Personalized Medicine Caucus and has been credited with contributing to policy outcomes including the 21st Century Cures Act (2016), CMS reconsideration of NGS-based testing coverage (2018-2019), and the NCQA colorectal cancer screening measure.

PMC generates revenue primarily through tiered annual membership dues paid by over 200 member institutions. Dues range from $500 annually for patient advocacy groups to $38,000 annually for large public corporations, with intermediate tiers for small public corporations ($19,000), private corporations ($3,500-$7,150), strategic partners ($1,700-$3,700), trade associations, and research/education/clinical care institutions. Member segments include large and emerging pharmaceutical companies (Pfizer, Bristol Myers Squibb, Eli Lilly), diagnostic companies (Labcorp, Quest Diagnostics, Roche Diagnostics, Guardant Health, GRAIL), academic medical centers (Mayo Clinic, MD Anderson Cancer Center), patient advocacy groups (LUNGevity Foundation, American Association of Kidney Patients), trade associations (PhRMA), strategic partners, and IT/informatics companies. The organization operates at a small scale (1-10 employees) and is governed by a Board of Directors representing member institutions.

PMC's product surface includes the Annual Personalized Medicine Conference (scheduled for November 18, 2026), research reports and publications, the PGx Drug-Gene Associations Database maintained with Manchester University School of Pharmacy, educational platforms (Personalized Medicine 101, More Than a Number, A Consumer's Guide to Genetic Health Testing), the Addressing Disparities in Research Report, and Congressional briefings and policy committee meetings. Working groups span AI, Health Data, IRA, and Pharmaceutical & Diagnostics topics. In January 2026, Gina Ross Murdoch was appointed President and CEO, succeeding founding president Edward Abrahams, who retired December 31, 2024 after 20 years of service. The organization holds a Candid 2026 Platinum Seal of Transparency and a Charity Navigator three-star rating.

Name

Personalized Medicine Coalition

Legal name

Personalized Medicine Coalition

Website

https://personalizedmedicinecoalition.org

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

Personalized Medicine Coalition is a Washington, D.C.-based nonprofit membership coalition that educates, advocates, and develops evidence to advance personalized medicine for over 200 member institutions across the healthcare ecosystem.

Ownership category

akta.pro rank

Product category

Healthcare Policy Advocacy

NAICS

Voluntary Health Organizations (813212), Business Associations (813910)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Medical Missions & Global Health NGOs (BPAGACAI)

akta.pro secondary industry

Hospitals, Clinics & Charitable Healthcare Providers (BPAGACAB)

Keywords

• Personalized medicine advocacy
• Healthcare policy education
• Precision medicine coalition
• Biomedical research advocacy
• Membership healthcare organization

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others, Technology or R&D

Revenue model

1. Membership Dues: PMC generates revenue through annual membership dues from healthcare institutions, pharmaceutical companies, diagnostic companies, patient advocacy groups, research organizations, and other stakeholders in the personalized medicine ecosystem. Dues range from $500 (Patient Advocacy Groups) to $38,000 (Large Public Corporations) based on organization type and size.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Personalized Medicine Coalition (PMC) is a private nonprofit membership-based advocacy organization that advances personalized medicine through a three-pronged approach of education, advocacy, and evidence development. The Coalition convenes pharmaceutical companies, diagnostic companies, patient advocacy groups, healthcare institutions, payers, and policymakers, and offers tiered annual membership, an annual conference, policy briefings, working groups, and research publications. Revenue is generated primarily through annual membership dues ranging from $500 for patient advocacy groups to $38,000 for large public corporations.

Product overview

The Personalized Medicine Coalition (PMC) is a membership-based advocacy and education organization, not a traditional product company. PMC operates as a platform offering educational resources, research publications, conferences, and policy advocacy services to its 200+ member institutions across the healthcare ecosystem. The organization's core offerings include the Annual Personalized Medicine Conference, research reports on FDA personalized medicine progress, educational platforms like Personalized Medicine 101 and More Than a Number, the PGx Drug-Gene Associations database, and multimedia resources. These offerings work together to advance PMC's mission of promoting understanding and adoption of personalized medicine concepts, services, and products.

Differentiator

Problem solved

Functional benefit

Products and services

• Annual Personalized Medicine Conference An annual conference offering attendees an opportunity to develop collaborative solutions to shared challenges in personalized medicine, featuring exchanges with leading business executives, clinicians, journalists, and patient advocates in an intimate setting. Members receive priority consideration for speaking opportunities and discounted registration.
• Personalized Medicine 101 An educational platform explaining what personalized medicine is, who it helps, and how it benefits patients through prevention, diagnosis, and treatment strategies. Targeted at decision-makers, providers, and the public to build understanding of personalized medicine.
• More Than a Number A flagship educational platform designed to empower patients to advocate for healthcare tailored to their biological characteristics, circumstances, and values. Targeted at patient communities and the general public.
• A Consumer's Guide to Genetic Health Testing A consumer-facing guide describing what genetic tests are, outlining the types of information they provide, and explaining key considerations before ordering at-home genetic tests. Targeted at individual consumers exploring direct-to-consumer genetic testing.
• PGx Drug-Gene Associations Database A quarterly cross-reference analysis comparing the FDA's Table of Pharmacogenetic Associations and the CPIC Clinical Guidelines on drug-gene associations for prescribing and dosing decisions. Conducted on PMC's behalf by Manchester University School of Pharmacy faculty and targeted at researchers, genetic test developers, and healthcare decision-makers.
• Addressing Disparities in Personalized Medicine Research Report A research report containing strategies to improve diversity and inclusion in personalized medicine research, developed through a Health Equity Task Force engagement with more than 60 community leaders, including 38 from historically underrepresented communities. Targeted at researchers, policymakers, and patient advocacy organizations.
• Personalized Medicine at FDA Research Reports Research reports tracking the progress of personalized medicine at the U.S. Food and Drug Administration, including annual assessments of new drug approvals classified as personalized medicines, clinical practice gap analyses, and strategic plans. Two of these reports rank in the top 25% of medicine's most-read research articles.
• Multimedia Resources Library
• PMC Annual Policy Agenda An annual policy agenda publication outlining PMC's advocacy priorities to promote innovation and the delivery of high-quality healthcare in the era of personalized medicine. Distributed to members, policymakers, and Congressional offices.
• PMC Membership Program A tiered annual membership program providing members with access to PMC's member database of personalized medicine leaders, participation in policy committees and working groups (AI, Health Data, IRA, Pharmaceutical & Diagnostics), priority consideration for conference speaking opportunities, reduced conference registration, and access to PMC publications and reports.

Quantifiable outcome

• More than one third of new drug approvals by FDA in 2023 were personalized medicines
• +3 more outcomes

Named customers13 records

Segments7 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered major and core.

• Biocom CaliforniamajorStrategic or Co-development Partner · 5 May 2026PMC and Biocom co-hosted an educational briefing in cooperation with the Congressional Personalized Medicine Caucus titled 'Personalized Medicine and Rare Disease in Children' on May 5, 2026. The briefing examined the diagnostic odyssey that patients with rare conditions endure.
• Congressional Kidney CaucusmajorStrategic or Co-development Partner · 12 December 2024PMC, the Congressional Personalized Medicine Caucus, and the Congressional Kidney Caucus co-hosted an educational briefing for Congressional staffers titled 'Personalized Medicine and Kidney Care' examining how personalized medicine is benefiting kidney transplant patients.
• Congressional Personalized Medicine CaucuscoreStrategic or Co-development PartnerPMC works in close coordination with the Congressional Personalized Medicine Caucus, a bipartisan group of U.S. Senators and Representatives. The caucus supports legislation to advance personalized medicine and hosts briefings to educate Congressional colleagues about the field's importance to healthcare. Current co-chairs include Rep. John Moolenaar (R-MI-02) and Sen. Tim Scott (R-SC).
• Manchester University School of PharmacymajorStrategic or Co-development PartnerPharmacogenomics faculty at Manchester University conduct quarterly comparative analysis of FDA and CPIC drug-gene association resources on behalf of PMC. The analysis centralizes information about changes in pharmacogenomic information to help researchers, genetic test developers, and healthcare decision-makers keep up with the field.
• Health Equity Task Force (HETF)majorStrategic or Co-development PartnerPMC convened a Health Equity Task Force comprising 25 research, data management, and community leaders from underrepresented communities to develop recommendations for addressing disparities in personalized medicine research. The task force includes members from organizations such as AARP, Morehouse School of Medicine, NIH's All of Us Research Program, and various community health organizations.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Pharmaceutical Research and Manufacturers of America (PhRMA): The primary U.S. pharmaceutical industry trade association that conducts federal advocacy, lobbying, and policy shaping on drug pricing, reimbursement, and FDA pathways. Highly comparable in mission and Congressional access model to PMC, and PhRMA is itself a PMC member, illustrating how closely they sit in the same ecosystem.
• Biotechnology Innovation Organization (BIO): The largest U.S. biotech trade association running federal advocacy, working groups, and an annual conference similar to PMC's model. Comparable because it also serves a cross-sector biotech/diagnostic membership and engages policymakers on FDA and reimbursement issues relevant to personalized medicine.
• AdvaMed: The leading U.S. medical device and diagnostics trade association. AdvaMed is the closest direct analogue for PMC's diagnostic-company constituency (Labcorp, Quest, Roche, Guardant, GRAIL), running a comparable dues-based advocacy and Congressional engagement model centered on diagnostic and device policy.
• Friends of Cancer Research: A Washington, D.C.-based policy and advocacy organization driving legislative and regulatory reforms in oncology research and drug development. Highly comparable to PMC's three-pronged education/advocacy/evidence-development approach, focused specifically on cancer policy.
• FasterCures (Milken Institute): A center within the Milken Institute focused on accelerating medical research and patient access through policy advocacy and cross-sector convening. Shares PMC's model of bringing together researchers, industry, and patient groups to address systemic barriers to adoption.
• American Association for Cancer Research (AACR): A major membership-based scientific and advocacy organization advancing cancer research through publications, working groups, an annual conference, and policy engagement. Directly comparable to PMC in operating model and overlap of MD Anderson, Mayo Clinic, and pharma members.
• National Health Council: A Washington, D.C.-based membership coalition of patient advocacy organizations and health-related nonprofits. Highly comparable to PMC's membership and advocacy model, with overlapping patient-advocacy members (e.g., LUNGevity, AAKP) and a similar dues-funded operating structure.
• Global Alliance for Genomics and Health (GA4GH): An international policy-framing alliance developing standards and frameworks for genomic and health data sharing. Comparable to PMC in mission around genomic and personalized medicine governance, with a working-group-driven operating model and similar funder/diagnostician stakeholder mix.
• Research!America: A nonprofit advocacy alliance dedicated to increasing federal funding for health and medical research. Shares PMC's education-and-advocacy model, Congressional engagement tactics, and membership coalition of research institutions, industry, and patient organizations.
• Healthcare Information and Management Systems Society (HIMSS): A large global membership-based advocacy organization advancing health information technology through policy, education, and an annual conference. Comparable in scale, dues-based model, working-group structure, and policy-influence footprint across the healthcare ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/personalized-medicine-coalition
• Xx.com/permedcoalition

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Personalized Medicine Coalition